Bogart Wealth LLC’s Lantern Pharma LTRN Stock Holding History

Bogart Wealth LLC’s Portfolio LTRN Stock Details LTRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-75	Closed	–	–	1138
2022 Q3	$0	Buy	+75	New	+$403	﹤0.01%	1077

Other funds holding LTRN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RAM

Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

WWM

Wolff Wiese Magana Carslbad, California $217M AUM 47.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bogart Wealth LLC's LTRN Position: Q4 2022 in Review

Bogart Wealth LLC sold out of Lantern Pharma (LTRN) in Q4 2022, closing a stake of 75 shares.

Bogart Wealth LLC first reported a position in LTRN in Q3 2022 and held it in 1 quarter. The position peaked at $0 in Q3 2022. 23 funds tracked by Wall St. Rank hold LTRN as of Q4 2022.

Bogart Wealth LLC reported no remaining Lantern Pharma position as of Q4 2022 after selling out during the quarter.
Bogart Wealth LLC sold 75 Lantern Pharma shares in Q4 2022.
Bogart Wealth LLC first reported a position in Lantern Pharma in Q3 2022 and held it in 1 quarter.
Bogart Wealth LLC's Lantern Pharma position peaked at $0 in Q3 2022.
23 funds tracked by Wall St. Rank held Lantern Pharma as of Q4 2022.

Based on Bogart Wealth LLC's 13F filing for Q4 2022, filed 6 Feb 2023.